180 Life Sciences CorpNASDAQ ATNF Stock Report

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California and currently employs 7 full-time employees. The company went IPO on 2017-06-07. The firm is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by research and combination therapy. The Company’s programs developing novel drugs for treating distinct inflammatory diseases. The firm has three product development platforms Anti-TNF platform, SCAs platform and a7nAChR platform. The Anti-TNF platform is focused on the fibrosis and anti-tumor necrosis factor (anti-TNF). The SCAs platform is focused on the drugs that are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). The a7nAChR platform, which is focused on the alpha 7 nicotinic acetylcholine receptor (a7nAChR). The firm is conducting clinical trials only for certain indications under the anti-TNF platform. The firm is also undertaking preclinical research and development activities for the SCA and the a7nAChR platforms.